Affiliation: University of Copenhagen
- Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency?Merete Paludan
Department of Oncology, Aarhus University Hospital, Denmark
Acta Oncol 45:818-22. 2006..Concern about pulmonary toxicity should not be prohibitive for future studies targeting limitations to dose and volume...
- Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancerNeil Kopek
Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
Radiother Oncol 93:402-7. 2009..To determine the prognostic role of co-morbidity in medically inoperable early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT)...
- Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patientsTrine Lembrecht Jørgensen
Department of Oncology, Odense University Hospital, Odense, Denmark
Gynecol Oncol 127:367-74. 2012..Objectives of this study were to evaluate the significance of comorbidity and age ≥70 years on receiving cytoreductive surgery, standard combination chemotherapy (TC), adherence to TC treatment, and prognosis...
- Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countriesPia Baumann
Division of Oncology and Hospital Physics, Radiumhemmet Karolinska University Hospital, Sweden
Acta Oncol 45:787-95. 2006..EQD2 (> v.s.<55.6 Gy) showed a statistically significant benefit survival for the higher doses. SBRT for stage I NSCLC results in favourable local control not inferior to fractionated RT and with acceptable toxicity...